Gut Microbiota Signatures in Colorectal Cancer As a Potential Diagnostic Biomarker in the Future: A Systematic Review

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2024 Jul 27

PMID 39063179

Authors

Lucian-Flavius Herlo

Andreea Salcudean

Roxana Sirli

Stela Iurciuc

Alexandra Herlo

Andreea Nelson-Twakor

Luana Alexandrescu

Raluca Dumache

Affiliations

Soon will be listed here.

Abstract

The gut microbiota has acquired significant attention in recent years for its potential as a diagnostic biomarker for colorectal cancer (CRC). In this literature review, we looked at the studies exploring alterations in gut microbiota composition associated with CRC, the potential mechanisms linking gut dysbiosis to CRC development, and the diagnostic approaches utilizing gut microbiota analysis. Our research has led to the conclusion that individuals with CRC often display alterations in their gut microbiota composition compared to healthy individuals. These alterations can include changes in the diversity, abundance, and type of bacteria present in the gut. While the use of gut microbiota as a diagnostic biomarker for CRC holds promise, further research is needed to validate its effectiveness and standardize testing protocols. Additionally, considerations such as variability in the microbiota composition among individuals and potential factors must be addressed before microbiota-based tests can be widely implemented in clinical practice.

Citing Articles

Microbiota and Inflammatory Markers: A Review of Their Interplay, Clinical Implications, and Metabolic Disorders.

Pena-Duran E, Garcia-Galindo J, Lopez-Murillo L, Huerta-Huerta A, Balleza-Alejandri L, Beltran-Ramirez A Int J Mol Sci. 2025; 26(4).

PMID: 40004236 PMC: 11854938. DOI: 10.3390/ijms26041773.

Unraveling the Complex Interplay Between Neuroinflammation and Depression: A Comprehensive Review.

Salcudean A, Popovici R, Pitic D, Sarbu D, Boroghina A, Jomaa M Int J Mol Sci. 2025; 26(4).

PMID: 40004109 PMC: 11855341. DOI: 10.3390/ijms26041645.

Impact of Preoperative and Intraoperative Factors on Postoperative Outcomes in Patients with Colorectal Cancer: A 10-Year Retrospective Study.

Herlo L, Golu I, Herlo A, Virzob C, Alin I, Iurciuc S Diseases. 2025; 13(1.

PMID: 39851480 PMC: 11765074. DOI: 10.3390/diseases13010016.

Healing from Within: How Gut Microbiota Predicts IBD Treatment Success-A Systematic Review.

Alexandrescu L, Nicoara A, Tofolean D, Herlo A, Nelson Twakor A, Tocia C Int J Mol Sci. 2024; 25(15).

PMID: 39126020 PMC: 11313389. DOI: 10.3390/ijms25158451.

References

Tocia C, Dumitru I, Alexandrescu L, Petcu L, Dumitru E . Does rifaximin offer any promise in Crohn's disease in remission and concurrent irritable bowel syndrome-like symptoms?. Medicine (Baltimore). 2021; 100(1):e24059. PMC: 7793373. DOI: 10.1097/MD.0000000000024059. View

Sheng Q, He K, Li J, Zhong Z, Wang F, Pan L . Comparison of Gut Microbiome in Human Colorectal Cancer in Paired Tumor and Adjacent Normal Tissues. Onco Targets Ther. 2020; 13:635-646. PMC: 6982458. DOI: 10.2147/OTT.S218004. View

Hou X, Zheng Z, Wei J, Zhao L . Effects of gut microbiota on immune responses and immunotherapy in colorectal cancer. Front Immunol. 2022; 13:1030745. PMC: 9681148. DOI: 10.3389/fimmu.2022.1030745. View

Geng J, Fan H, Tang X, Zhai H, Zhang Z . Diversified pattern of the human colorectal cancer microbiome. Gut Pathog. 2013; 5(1):2. PMC: 3599420. DOI: 10.1186/1757-4749-5-2. View

Kordahi M, Stanaway I, Avril M, Chac D, Blanc M, Ross B . Genomic and functional characterization of a mucosal symbiont involved in early-stage colorectal cancer. Cell Host Microbe. 2021; 29(10):1589-1598.e6. PMC: 8979638. DOI: 10.1016/j.chom.2021.08.013. View

Jia W, Xie G, Jia W . Bile acid-microbiota crosstalk in gastrointestinal inflammation and carcinogenesis. Nat Rev Gastroenterol Hepatol. 2017; 15(2):111-128. PMC: 5899973. DOI: 10.1038/nrgastro.2017.119. View

Zou S, Fang L, Lee M . Dysbiosis of gut microbiota in promoting the development of colorectal cancer. Gastroenterol Rep (Oxf). 2018; 6(1):1-12. PMC: 5806407. DOI: 10.1093/gastro/gox031. View

Nenkov M, Ma Y, Gassler N, Chen Y . Metabolic Reprogramming of Colorectal Cancer Cells and the Microenvironment: Implication for Therapy. Int J Mol Sci. 2021; 22(12). PMC: 8230539. DOI: 10.3390/ijms22126262. View

Ispas S, Tuta L, Botnarciuc M, Ispas V, Staicovici S, Ali S . Metabolic Disorders, the Microbiome as an Endocrine Organ, and Their Relations with Obesity: A Literature Review. J Pers Med. 2023; 13(11). PMC: 10672252. DOI: 10.3390/jpm13111602. View

10.

Cheng W, Kantilal H, Davamani F . The Mechanism of Toxin Contributes to Colon Cancer Formation. Malays J Med Sci. 2020; 27(4):9-21. PMC: 7444842. DOI: 10.21315/mjms2020.27.4.2. View

11.

Jaspan V, Lin K, Popov V . The impact of anthropometric parameters on colorectal cancer prognosis: A systematic review and meta-analysis. Crit Rev Oncol Hematol. 2021; 159:103232. DOI: 10.1016/j.critrevonc.2021.103232. View

12.

Ismael S, Rodrigues C, Santos G, Castela I, Barreiros-Mota I, Almeida M . IPA and its precursors differently modulate the proliferation, differentiation, and integrity of intestinal epithelial cells. Nutr Res Pract. 2023; 17(4):616-630. PMC: 10375328. DOI: 10.4162/nrp.2023.17.4.616. View

13.

Bhimani N, Wong G, Molloy C, Pavlakis N, Diakos C, Clarke S . Cost of treating metastatic colorectal cancer: a systematic review. Public Health. 2022; 211:97-104. DOI: 10.1016/j.puhe.2022.06.022. View

14.

Sadeghi M, Mestivier D, Sobhani I . Contribution of pks+ (. ) to Colon Carcinogenesis. Microorganisms. 2024; 12(6). PMC: 11205849. DOI: 10.3390/microorganisms12061111. View

15.

Wirbel J, Pyl P, Kartal E, Zych K, Kashani A, Milanese A . Meta-analysis of fecal metagenomes reveals global microbial signatures that are specific for colorectal cancer. Nat Med. 2019; 25(4):679-689. PMC: 7984229. DOI: 10.1038/s41591-019-0406-6. View

16.

Hofmann B . Ethical issues with colorectal cancer screening-a systematic review. J Eval Clin Pract. 2016; 23(3):631-641. DOI: 10.1111/jep.12690. View

17.

Li Y, Cao H, Fei B, Gao Q, Yi W, Han W . Gut Microbiota Signatures in Tumor, Para-Cancerous, Normal Mucosa, and Feces in Colorectal Cancer Patients. Front Cell Dev Biol. 2022; 10:916961. PMC: 9201480. DOI: 10.3389/fcell.2022.916961. View

18.

Mindrescu N, Guja C, Jinga V, Ispas S, Curici A, Nelson Twakor A . Interactions between Gut Microbiota and Oral Antihyperglycemic Drugs: A Systematic Review. Int J Mol Sci. 2024; 25(6). PMC: 10971180. DOI: 10.3390/ijms25063540. View

19.

Thomas A, Manghi P, Asnicar F, Pasolli E, Armanini F, Zolfo M . Metagenomic analysis of colorectal cancer datasets identifies cross-cohort microbial diagnostic signatures and a link with choline degradation. Nat Med. 2019; 25(4):667-678. PMC: 9533319. DOI: 10.1038/s41591-019-0405-7. View

20.

Dawson P, Karpen S . Intestinal transport and metabolism of bile acids. J Lipid Res. 2014; 56(6):1085-99. PMC: 4442867. DOI: 10.1194/jlr.R054114. View